A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of ZVS101e Administered as a Single Monocular Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Incidence of ocular and systemic adverse events (AEs) after ZVS101e treatment
研究概览
简要总结
The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.
详细描述
This is a single-arm, open-label, and multi-center study of ZVS101e in patients with BCD. Up to 24 subjects are expected to be enrolled. Each participant will receive ZVS101e by subretinal injection in one eye on a single occasion. Safety, efficacy and vector shedding characteristics of ZVS101e are then measured over 180 days. Participants will subsequently enter a long-term follow-up study over a 4.5-year period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, sign the informed consent form, and be able to complete the whole trial processes as required by the protocol;
- •2. Patients with clinical diagnosis of Bietti's crystalline dystrophy (BCD) (age ≥ 18 years) (including the critical value, and the age is based on the time of signing the informed consent form);
- •3. Genetic test confirmed to carry two pathogenic variants of CYP4V2 and carry no pathogenic mutations of other ophthalmic genetic diseases;
- •4. The study eye must meet the following requirements: Best-corrected visual acuity between 2.3 LogMAR and 0.5 LogMAR (including 2.3 LogMAR and 0.5 LogMAR).
排除标准
- •1. Subjects with insufficient viable retinal cells, or macular retinal less than 100 μm thick;
- •2. Pre-existing eye conditions in the study eye that the investigator determines could interfere with ocular evaluation, preclude surgery, interfere with interpretation of study endpoints or pose surgical complications;
- •3. The study eye has been treated with the following intraocular procedures: retinal detachment surgery, vitrectomy;
- •4. The study eye has been treated with other drugs within 3 months that could affect the evaluation of the investigational drug (such as ranibizumab, bevacizumab, aflibercept, conbercept);
- •5. Currently taking or may require systemic medications that can cause ocular toxicity, such as psoralen, risedronate, or tamoxifen;
- •6. Those with the following laboratory abnormalities which are clinically significant:
- •Liver function: chronic liver disease, ALT increased > 2 times the upper limit of normal;
- •Hypertension, mean SBP ≥ 160 mmHg or mean DBP ≥ 100 mmHg;
- •Coagulation function (prothrombin time ≥ upper limit of normal (3 seconds' longer), activated partial thromboplastin time ≥ upper limit of normal (10 seconds' longer));
- •Serum virology test: Active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab) or syphilis antibody positive;
- •7. Patients with rAAV8 neutralizing antibody titer ≥ 1:1000;
- •8. Complicating systemic diseases (such as medical conditions causing immunosuppression) that would preclude the gene transfer, ocular surgery and drug in vivo activity;
- •9. Known drug allergy to the drug planned to be used in the study;
- •10. Patients who cannot communicate or cooperate with medical staff due to neurological, mental illness or language disorder, which affects patient compliance;
- •11. Treatment of either eye with gene therapy drugs for BCD and other ocular diseases, including but not limited to other viral vector gene therapies, mRNA therapy, etc.;
- •12. Has or has had a systemic immune-compromising disease;
- •13. Subjects of reproductive age without any effective contraception and female subjects who have tested positive for pregnancy or are lactating at screening or baseline;
- •14. A condition that, in the opinion of the investigator, would preclude participation in the study.
研究组 & 干预措施
Experimental
Dose escalation and expansion of ZVS101e. All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye.
干预措施: ZVS101e (Drug)
结局指标
主要结局
Incidence of ocular and systemic adverse events (AEs) after ZVS101e treatment
时间窗: Up to day 180
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment.
Mean change from baseline in BCVA (LogMAR)
时间窗: Up to day 180
BCVA of both eyes will be assessed using the early treatment of diabetic retinopathy study (ETDRS) chart.
Incidence of ocular and systemic serious adverse events (SAEs) after ZVS101e treatment
时间窗: Up to day 180
A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following: Results in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events.
次要结局
- Change from Baseline in visual field(Up to day 180)
- Change from Baseline in contrast sensitivity(Up to day 180)
- Change from Baseline in retinal thickness(Up to day 180)
- Change from Baseline in NEI VFQ-25 total score(Up to day 180)
- Change from Baseline in color vision(Up to day 180)
- Change from Baseline in microperimetry(Up to day 180)
- Change from Baseline in mfERG(Up to day 180)